InvestorsHub Logo
Followers 0
Posts 21
Boards Moderated 0
Alias Born 04/19/2017

Re: BioBull1 post# 5852

Friday, 05/05/2017 12:08:33 PM

Friday, May 05, 2017 12:08:33 PM

Post# of 6306
Or -- the price is so beaten down that it's a great buy. I agree management has made mistakes. That's the bad part. The NSS is performing about twice as good as the FDA performance criteria. The clinical reversions is a non-issue. Not all patients convert. This is killing it over no treatment. And a patient yo-yo is normal. They are teetering on the edge. Probably due to details of their injury. This is a strong buy.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.